When Johnson & Johnson ($JNJ) Innovation debuted about a year ago, R&D chief Paul Stoffels promised to build an interconnected, global operation that would sink some deep roots into the world’s busiest biotech hubs. On Thursday, the group showed off just how far it had come in a short time, highlighting a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers–all aimed at putting the multinational pharma giant on the cutting edge of new product development.
{iframe}http://www.fiercebiotech.com/story/jj-innovation-shows-its-new-summer-lineup-biotech-pacts/2014-06-19{/iframe}